💥BREAKING:SEC APPROVES IN-KIND REDEMPTIONS FOR ALL SPOT ETFs.GIANTS LIKE GOLDMAN SACHS AND JPMORGAN CAN MOVE PHYSICAL BTC IN AND OUT.THIS IS A GAME CHANGER. 🤯 https://t.co/NC1PmkIrnd ...

Business Relationship - JPMorgan is in advanced talks to replace Goldman Sachs in its credit-card joint venture with Apple [1]

Yeah, a lot of names down this morning on earnings, Carl. Yep. And not indeed.Let's get the openings all this morning in the CNBC real time exchange of the big board. It's Evelyn Hill celebrating its 10th listing anniversary retirement solution to the said, Jim, seven or six consecutive record closes in a row and no 1% move in over a month. No, I mean there's no doubt how but what's amazing is is that we have a sea of green even though we just mentioned some serious declines and some of that is David's worl ...

Core Viewpoint - Advanced Micro Devices (AMD) has received a positive endorsement from BofA Securities, maintaining a 'Buy' rating and raising its price target from $175 to $200, indicating a potential increase of about 15% from its last closing price of $173 [1][4]. Group 1: Price Target and Stock Performance - The new price target of $200 represents a 15% increase from AMD's last closing price of $173 [1]. - AMD's stock has rallied 11% over the past week and ended the previous session up over 4% [1]. Group 2: Earnings Expectations and Revenue Projections - BofA expects AMD to exceed consensus in both Q2 and Q3 earnings, forecasting revenues of $7.5 billion and $8.5 billion, respectively [7]. - For the full year 2025, BofA projects AMD's revenue to reach $33 billion and earnings per share of $4.10, both surpassing current Wall Street estimates [7]. Group 3: Market Opportunities and Drivers - Potential resumption of AI chip shipments to China in the second half of the year could contribute up to $1 billion in sales in 2025 and as much as $2 billion by 2026 [4]. - AMD is benefiting from stronger-than-expected pricing for its MI355X chips, with units selling for over $20,000, exceeding the consensus estimate of $17,000 [5]. - Strong demand for cloud-related GPUs, improving year-over-year comparisons in the PC segment, and steady enterprise interest from companies like Hewlett Packard Enterprise and Texas Instruments are also positive drivers [5]. Group 4: Market Share Projections - AMD is projected to capture more than 30% of the global CPU market by 2026, up from just under 20% in 2023 [8]. - Its share of the competitive AI GPU space could grow to 4% to 5%, supported by strategic shifts and manufacturing uncertainties at Intel [8]. Group 5: Analyst Ratings - Wall Street remains bullish on AMD stock, with Goldman Sachs reiterating a 'Buy' rating with a $140 target, while HSBC upgraded AMD to 'Buy' with a $200 target [8][9]. - Citi maintained a 'Hold' but raised its target from $120 to $145, indicating improved expectations [9].

Group 1 - Morgan Stanley projects the S&P 500 to reach 7,200 by mid-2026, indicating a 12% increase from the last close of 6,389 [1] - The bullish outlook is supported by favorable economic factors, including a "rolling recovery" environment, improved operating leverage, AI adoption, a weakening U.S. dollar, and tax savings from the Inflation Reduction Act [2][4] - Anticipated interest rate cuts by the Federal Reserve in early 2026 and easing year-over-year growth comparisons further bolster the positive outlook [3] Group 2 - Oppenheimer raised its year-end S&P 500 target to 7,100 from 5,950, citing robust corporate earnings and favorable macroeconomic conditions [5] - Other institutions have also revised their forecasts upward, including BMO (6,700), Goldman Sachs (6,600), and Bank of America (6,300) [5] - Despite the bullish sentiment from many firms, Evercore ISI and HSBC remain cautious with the lowest targets at 5,600 [7]

Core Viewpoint - Iovance Biotherapeutics' stock has seen a significant decline, down approximately 75% from its peak in December, leading to mixed opinions among analysts regarding its valuation and future potential [1][2][3]. Group 1: Analyst Ratings and Price Targets - Chardan Capital maintains a buy rating with a price target of $25, suggesting a potential gain of about 720% from the current price of $3.05 [2]. - The consensus price target for Iovance is $10 per share, indicating a potential average gain of 228% [3]. Group 2: Product Approval and Market Potential - The FDA approved Iovance's first product, Amtagvi, in February 2024, which is a cell-based treatment for advanced melanoma [5]. - In clinical trials, Amtagvi demonstrated a tumor shrinkage response in 31.5% of patients who had previously failed PD-1 blocking therapies [6]. - Among 41 patients evaluated post-approval, 20 showed smaller tumors or no tumors, with a response rate of 60.9% in those with limited prior treatments [7]. Group 3: Challenges Facing Iovance - Goldman Sachs downgraded Iovance to sell, citing concerns over a slower-than-expected launch of Amtagvi [8]. - The launch faces challenges including the FDA's approval based on tumor shrinkage rather than overall survival benefits, a small sales team, and the complex administration of the treatment [9][10]. - Sales for Amtagvi reached $43.6 million in Q1 2025, which is below expectations for a blockbuster product [11]. Group 4: Financial Outlook and Market Valuation - Iovance's market cap is approximately $1.05 billion, which is considered low for a biotech company with a new product [12]. - Management projects sales between $250 million and $300 million for the year, with biotech stocks typically trading at mid-to-high single-digit multiples of trailing sales [12]. - The resignation of the CFO raises concerns about future sales guidance, as such changes are often associated with disappointing forecasts [14].

Market Trend - Goldman Sachs' Peter Oppenheimer advised investors to shift to international stocks due to the US market's high valuation [1] - The shift to international stocks is expected to yield further benefits this year [1]

RT Crypto.com Research & Insights (@cryptocom_rni)Crypto Market Pulse Weekly:📈 US spot ETH ETFs outpaced BTC ETFs in net inflows for 7 days✍️ White House is set to release its digital asset report on July 30💫 Goldman Sachs and BNY Mellon launched tokenised money market fundsThe details 👇https://t.co/5hEW4SICb0 https://t.co/ClUn98o8E5 ...

Business Strategy - Goldman Sachs is reorganizing its Tokyo leadership to strengthen its capital markets division [1] - The restructuring aims to capitalize on increased dealmaking opportunities resulting from Japan's corporate governance reforms [1]

Market Outlook - Goldman Sachs raised its target for Chinese stocks [1] - Improving prospects for a US-China trade deal cited as a key factor [1] - Removal of a key overhang for the market expected [1]